Core Insights - BioCryst Pharmaceuticals will present nine abstracts from its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting in Philadelphia from February 27 to March 2, 2026 [1][2] HAE Portfolio Developments - Six abstracts will focus on new clinical trial and real-world outcomes with ORLADEYO (berotralstat), the first targeted oral prophylactic therapy for HAE patients aged 2 and older [2] - Three abstracts will present new clinical trial outcomes with navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor [2] - A late-breaking presentation will highlight positive interim results from the ALPHA-SOLAR trial, showing sustained HAE attack suppression with navenibart administered every 3 or 6 months [2][4] Strategic Focus - The data presented reflects BioCryst's strategy to expand and diversify its HAE portfolio, aiming to provide meaningful treatment options that align with patient needs [3] - The company is advancing programs like navenibart and launching an expanded pediatric indication for ORLADEYO [3] Presentation Details - BioCryst will present eight posters on February 27, 2026, and one late-breaking abstract on March 1, 2026, at the Convention Center, Level 2, Hall E [4] Product Information - ORLADEYO (berotralstat) is the first oral therapy specifically designed to prevent HAE attacks in patients aged 2 years and older [5] - Navenibart is an investigational monoclonal antibody being evaluated for long-term prevention of HAE attacks, with potential dosing every 3 or 6 months [6] Research Findings - Interim data from the APeX-P trial indicates that oral berotralstat reduces the rate of moderate and severe attacks in children aged 2 to less than 12 years [7] - Various posters will present real-world evidence on the impact of berotralstat on attack rates and healthcare resource utilization among patients with C1-inhibitor deficiency [7]